Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tobacco Use Disorder
Intervention: Memantine (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Adam Bisaga, M.D., Principal Investigator, Affiliation: New York State Psychiatric Institute
Overall contact:
Marc Scullin, Phone: (212)543-6542, Email: scullin@pi.cpmc.columbia.edu
Summary
One of nicotine's effects on the body is at the level of the NMDA receptors in the brain.
Memantine is a drug that also affects NMDA receptors, making it a candidate for the treatment
of nicotine addiction. The purpose of this study is to evaluate the effectiveness of
memantine using a laboratory model of smoking relapse in nicotine dependent volunteers. We
will compare the effects of memantine with bupropion, medication currently used to facilitate
smoking cessation.
Clinical Details
Official title: Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study
Primary outcome: Smoking Relapse
Detailed description:
Tobacco use is the leading preventable cause of death in the United States. Recent research
on the effects of nicotine on the brain and behavior presents an opportunity to advance
medication development. Neurotransmission at NMDA receptors in the brain is associated with
learning and memory and has been linked to many of nicotine's effects on humans. It is
possible that altering NMDA neurotransmission may be helpful in treating nicotine addiction.
The goal of this study is to evaluate the effects of memantine, an NMDA receptor antagonist,
using the laboratory model of smoking relapse in nicotine dependent volunteers. The effects
of memantine used in combination with bupropion, a medication currently used to facilitate
smoking cessation, will be compared to a placebo.
This double-blind study will consist of three phases (placebo, bupropion, and memantine).
Each phase will include 10 days of outpatient medication maintenance, followed by 5 days of
inpatient testing. During the outpatient phase, study visits will occur every 2 to 3 days.
During the first portion of inpatient stay, participants will not be permitted to smoke.
During the second portion of inpatient stay, smoking reinstatement will be modeled, as
participant will have opportunity to smoke. A variety of behavioral, subjective,
physiological, and performance measures will be assessed throughout the study.
Eligibility
Minimum age: 21 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- DSM-IV diagnosis of nicotine dependence with psychological dependence
- Smokes at least 15 cigarettes per day for the three months prior to enrollment
- Currently not seeking treatment for nicotine dependence
- Medically healthy on the basis of physical examination and medical history, vital
signs, EKG, and laboratory tests
- Females must use an effective method of contraception for the duration of the study
Exclusion Criteria:
- DSM-IV diagnosis of abuse or dependence on alcohol or drugs other than nicotine
- Current Axis I diagnosis or current treatment with psychotropic medications within the
three months prior to enrollment
- History of schizophrenia or other psychotic disorders, bipolar disorder, or anxiety
disorders
- Currently seeking treatment for nicotine disorders
- On parole or probation
- History of seizures or head trauma with loss of consciousness, brain contusion, or
fracture
- History of significant recent violent behavior
- Blood pressure greater than 150/90
- History of eating disorders
- History of allergic reaction to any of the study medications
- Pregnant
Locations and Contacts
Marc Scullin, Phone: (212)543-6542, Email: scullin@pi.cpmc.columbia.edu
New York State Psychiatric Institute, New York, New York 10032, United States; Recruiting
Adam Bisaga, M.D., Phone: 212-543-6542, Email: bisagaa@pi.cpmc.columbia.edu
Additional Information
Starting date: December 2006
Last updated: August 6, 2008
|
